Get the Stockscreener App
52.11
2.30%
1.17
After Hours:
52.00
-0.11
-0.21%
Ptc Therapeutics Inc stock is traded at $52.11, with a volume of 2.30M.
It is up +2.30% in the last 24 hours and up +6.70% over the past month.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
See More
Previous Close:
$50.94
Open:
$50.69
24h Volume:
2.30M
Relative Volume:
1.88
Market Cap:
$4.13B
Revenue:
$900.66M
Net Income/Loss:
$-453.20M
P/E Ratio:
-8.7727
EPS:
-5.94
Net Cash Flow:
$-274.19M
1W Performance:
+12.50%
1M Performance:
+6.70%
6M Performance:
+13.58%
1Y Performance:
+53.94%
1-Day Range:
$50.36
$52.70
1-Week Range:
$44.15
$52.70
52-Week Range:
$29.02
$58.38
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
52.11 | 4.04B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Truist | Buy |
| May-09-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-07-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-11-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-07-25 | Initiated | Scotiabank | Sector Perform |
| Dec-13-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-03-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Aug-26-24 | Resumed | UBS | Buy |
| May-20-24 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
Q3 EPS Forecast for PTC Therapeutics Decreased by Analyst - MarketBeat
PTC Therapeutics: Uncertainty Abounds Ahead Of Q2 EarningsI'm Upgrading To 'Hold' - Seeking Alpha
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
Bayforest Capital Ltd Purchases New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Y Intercept Hong Kong Ltd Sells 6,043 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Using data models to predict PTC Therapeutics Inc. stock movementSwing Entry Insight With Forecast Accuracy - Newser
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $86.00 - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up Following Analyst Upgrade - MarketBeat
Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval - BioPharma Dive
Bank of America Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price - MarketBeat
Barclays Forecasts Strong Price Appreciation for PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
UBS Group Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $120.00 at Cantor Fitzgerald - MarketBeat
PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains? - Yahoo Finance
Orsini Selected as Specialty Pharmacy Partner for PTC Therapeutics' SEPHIENCE™ (sepiapterin) - Yahoo Finance
36,246 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Purchased by Neo Ivy Capital Management - MarketBeat
Price Reversal in PTC Therapeutics Inc. Traders Watch CloselyBuy Low Sell High Stock Watch Strategy in Focus - beatles.ru
AI Tools Suggest PTC Therapeutics Inc. May Outperform This WeekSecure Return Focused Investment Plan Released - metal.it
PTC Therapeutics Inc. Breakout Confirmed by Volume MetricsBreakout Momentum Picks With Protection Outlined - metal.it
PTC To Challenge BioMarin In PKU With Oral Sephience - insights.citeline.com
PTC Therapeutics (NASDAQ:PTCT) Shareholders Are Still up 36% Over 1 Year Despite Pulling Back 7.4% in the Past Week - 富途牛牛
PTCT’s Future: A Game Changer? - StocksToTrade
Why Is PTC Therapeutics Stock Trading Higher Today?PTC Therapeutics (NASDAQ:PTCT) - Benzinga
PTC Therapeutics stock price target raised to $120 from $112 at Cantor Fitzgerald - Investing.com
PTC Therapeutics stock jumps as Truist raises price target on Sephience approval - Investing.com Canada
US FDA approves PTC Therapeutics' metabolic disorder drug - MSN
PTC Therapeutics stock rises as UBS raises price target following FDA approval - Investing.com Canada
These Analysts Increase Their Forecasts On PTC Therapeutics - Benzinga
PTC Therapeutics Receives Buy Rating Following FDA Approval of Sephience and Strategic Market Positioning - TipRanks
PTC Therapeutics (NASDAQ:PTCT) shareholders are still up 36% over 1 year despite pulling back 7.4% in the past week - simplywall.st
PTC Therapeutics (PTCT) Price Target Raised by Analyst - GuruFocus
FDA green lights broader label for PTC Thera’s Sephience for PKU - The Pharma Letter
PTC Therapeutics: Buy Rating Driven by Sephience Approval and Market Strategy - TipRanks
Positive Outlook for PTC Therapeutics: Buy Rating Affirmed Following Sephience Approval and Strategic Launch - TipRanks
PTC Therapeutics price target raised to $46 from $42 at Barclays - TipRanks
PTC Therapeutics Soars 10.31% on FDA Approval of Sephience - AInvest
How did PTCT's revenue and expenses trends shift in Q4 2024 compared to previous quarters - AInvest
PTC Therapeutics' Sephience Approval: A $1B+ Rare Disease Opportunity Unfolding - AInvest
FDA Approval Sparks Bullish Momentum In PTC Therapeutics — Here’s What Happened - Stocktwits
PTC Therapeutics (PTCT) Gains FDA Approval for Sephience in Phenylketonuria - GuruFocus
PTC Therapeutics Gains FDA Approval for Sephience - TipRanks
PTC's PKU drug scores US approval - FirstWord Pharma
PTC Therapeutics stock soars after FDA approval of PKU treatment By Investing.com - Investing.com Canada
PTC Therapeutics gets FDA nod for phenylketonuria treatment - Seeking Alpha
FDA Approval Boosts PTC Therapeutics (PTCT) with Sephience Launch - GuruFocus
PTC Therapeutics: Pioneering Rare Disease Innovation with Sephience and Kebilidi - AInvest
PTC Therapeutics' Sephience™: A Game-Changer for PKU and Shareholder Value - AInvest
FDA approves PTC Therapeutics’ Sephience for phenylketonuria treatment - Investing.com Australia
PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) | PTCT Stock News - GuruFocus
Is it the right time to buy PTC Therapeutics Inc. stockValue Investing Recommendation For Every Investor - jammulinksnews.com
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):